Article
Testosterone Replacement Therapy in the VA Setting
Men's Sexual Health Consult Collection
Fed Pract. 2008;25(suppl 2):1–25.
Author and Disclosure Information
James V. Felicetta, MD, Alvin M. Matsumoto, MD, Adrian Dobs, MD, Diala El-Maouche, MD, Glenn R. Cunningham, MD, Sumbul Beg, MD, Lara Al-Khoury Nabbout, MD
Dr. Felicetta is the chairman of the department of medicine at the Carl T. Hayden VA Medical Center, Phoenix, AZ, and a professor of clinical medicine at the University of Arizona, Tucson. Dr. Matsumoto is a professor in the department of medicine at the University of Washington School of Medicine, Seattle, WA, as well as the associate director of the Geriatric Research, Education and Clinical Center and the director of the clinical research unit at the VA Puget Sound Health Care System, all in Seattle, WA. Dr. Dobs is professor of medicine and oncology in the School of Medicine, and Dr. El-Maouche is a postdoctoral fellow in the division of endocrinology and metabolism, both at Johns Hopkins University, Baltimore, MD. Dr. Cunningham is a professor in the departments of medicine and molecular and cellular biology at Baylor College of Medicine, Houston, TX. He is also medical director of the Diabetes Program at St. Luke's Episcopal Hospital, Houston. Dr. Beg is a second-year fellow in endocrinology in the department of medicine at Baylor College of Medicine and the medical service at St. Luke's Episcopal Hospital. Dr. Nabbout is a visiting fellow in endocrinology in the medical service at St. Luke's Episcopal Hospital.
Statement of Need/Program Overview: Male hypogonadism has been found to be more common than was previously recognized and more likely to be prevalent among VA patients than among the general population. As testosterone replacement therapy (TRT) is commonly used to treat this condition, VA practitioners should have a comprehensive understanding of the diagnosis and treatment of older men with adult-onset hypogonadism, and the benefits and risks associated with TRT. Educational Objectives: After completing this activity, the participant should be better able to:
- Recall at least three conditions common among VA patients that are closely associated with adult-onset hypogonadism.
- Identify five adverse symptoms associated with adult-onset hypogonadism that testosterone replacement therapy (TRT) has been shown to ameliorate.
- Describe four clear indications for TRT in adult males.
- Discuss current recommendations regarding pretreatment screening and posttreatment monitoring of TRT.
Method of Participation: There are no fees for participating and receiving CME credit for this activity. During the period May 2008 through May 31, 2009 participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; and 3) go to www.cmeuniversity.com, click on "Find Post-test/Evaluation by Course" on the navigation menu, and search by Course ID: 5561. Upon successfully completing the post-test and evaluation, your certificate will be made available immediately.